• VolitionRX Limited (NYSE:VNRX) enters commercial stage for Nu.Q Vet Cancer Test.
• The first and only company to offer canine blood test for cancer
• Large addressable market with revenue opportunity.
• Continued to make strong progress with other Nu.Q® products

Company Overview VolitionRx Limited (NYSE: VNRX) is an innovative life sciences company focused on developing blood-based diagnostic tests for the early detection of a range of cancers, as well as other conditions. Founded in 2011, Volition has developed a suite of proprietary technologies, such as NuQ assays and NexTech platforms, to create simple, accurate and cost-effective tests for early-stage cancer diagnostics. The company’s tests are based on the use of nucleosomes, the structural units of DNA, to detect cancer in a simple blood test. VNRX’s tests have been developed to identify the presence of cancer and also to identify the type of cancer from the levels of nucleosomes in the blood as well as the different structure of nucleosomes. And...